Ionis Pharmaceuticals (IONS) Share-based Compensation (2013 - 2026)

Ionis Pharmaceuticals' Share-based Compensation history runs 14 years deep, the most recent figure standing at $43.3 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 45.62% year-over-year to $43.3 million; the TTM figure through Mar 2026 stood at $147.4 million (up 14.66% YoY), while the FY2025 annual figure was $133.9 million, up 2.82% from the prior year.
• Share-based Compensation was $43.3 million for Q1 2026 at Ionis Pharmaceuticals, roughly flat from $43.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $43.3 million in Q4 2025 to a low of $23.8 million in Q3 2022.
• Historically, Share-based Compensation has averaged $30.2 million across 5 years, with a median of $29.7 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation sank 30.7% in 2022, then jumped 45.62% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $25.7 million in 2022, then grew by 2.52% to $26.3 million in 2023, then soared by 37.26% to $36.1 million in 2024, then advanced by 19.84% to $43.3 million in 2025, then declined by 0.1% to $43.3 million in 2026.
• The last three Share-based Compensation figures came in at $43.3 million (Q1 2026), $43.3 million (Q4 2025), and $31.1 million (Q3 2025), per Business Quant data.